Kornimate/medical-research-clean huggingface dataset:
exercise is medicine: a pilot study

Conditions: Hypertension; Diabetes Mellitus

Summary: background: regular exercise is beneficial to patients with hypertension and/or diabetes mellitus. however, most patients cannot maintain exercise habit. the investigators had developed a program called the "exercise is medicine"(eim), combining motivational technique, information technology use and teaching exercise techniques. before using this intervention in a main randomized controlled trial, the investigators would like to test its feasibility and acceptability. it is hypothesized that this program is feasible and acceptable to patients. method: 40 patients with ht and/or dm will be recruited to attend the eim intervention. primary outcomes will be the rate of recruitment and rate of retention. other clinical outcomes will be obtained before and immediately after the 12-week program.


Eligibility criteria:
inclusion criteria: * clinic systolic bp(sbp) higher than 130mmhg (for ht class) because the hong kong primary care office guideline, as of jan 2019, regarded good control of sbp to be ≤130mmhg, or hba1c \>7% (for dm class) * self-reported regular exercise of ≤3 times per week - this cut-off is arbitrary but people who exercise more than 3 times may have little space for improvement; and these patients will unlikely be referred to eim when it is implemented in routine clinical practice, - who have used any mobile apps on their phone (because the intervention involve use of apps to monitor and remind regular exercise) exclusion criteria: * patients with diagnosed chronic obstructive lung disease and recent stroke (within last 12 months) are excluded because there are other evidence-proven and well-structured programmes for these patients in the hospital authority (ha), for instance, pulmonary rehabilitation program conducted by physiotherapy and/or occupational therapist in ha. - - acute myocardial infarction in last 6 months * ongoing angina * uncontrolled cardiac arrhythmia * acute diseases including known active endocarditis/acute pulmonary embolism, pulmonary infarction, deep vein thrombosis, acute aortic dissection, acute myocarditis * known aortic stenosis * known heart failure * known obstructive left main coronary artery stenosis * uncontrolled ventricular rates * complete heart block * known hypertrophic obstructive cardiomyopathy * mental impairment that limit co-operation * resting blood pressure with systolic blood pressure \>180mmhg or diastolic blood pressure \>110mmhg * known anaemia with haemoglobin level less than 11gm/dl * known uncorrected electrolyte imbalance * known uncontrolled hyperthyroidism. * for dm patients, patients with proliferative diabetic retinopathy and recent retinal bleeding (in last 12 months) are also excluded due to reports that vigorous exercise may increase blood pressure and led to retinal bleeding in these patients
biotherapy for mrsa enterocolitis

Conditions: Methicillin-Resistant Staphylococcus Aureus

Summary: methicillin-resistant staphylococcus aureus (mrsa) is one of the major sources of nosocomial infection. along with the widely application of antibiotics around perioperative period, mrsa infection is increasing by years.fecal microbial transplantation (fmt),infusion of fecal preparation from a healthy donor into the gi tract of a patient is being proposed as a novel therapeutic approach to modulate diseases associated with pathological imbalances within the resident microbiota, termed dysbiosis.it has been used to treat intestinal disease such as inflammatory bowel diseases and clostridium difficile infection, but no reports are available on its role in treating mrsa enteritis yet. vancomycin is the first choice to treat mrsa but can also lead to an increase in antibiotic resistant organisms such as vancomycin-resistant enterococci, methicillin-resistant staphylococcus aureus and transfer of antibiotic resistance genes among the microbial community. so fmt seems a more harmless and reasonable measure to treat similar diseases.

five cases from july, 2013 to february, 2014 were collected in jinling hospital.they developed unexplained high fever, bloating, nausea, vomit, a high stoma output or diarrhea in the color of yellow-green with copious amounts of mucus leading to dehydration and tachycardia after short time of operation (2-4d).we got the etiology diagnosis from all the patients' gastric juice cultures which revealed mrsa.vancocin cp had a dissatisfied effect,so fmt was supplied for treating mrsa.all the patients had a decreased intestinal flora species before fmt and the content of staphylococcus aureus almost reached half of total intestinal flora . patients' gut bacteria after fmt gradually agree with the donors' reflected the alleviative symptoms.

Eligibility criteria:
inclusion criteria: 1.18-70 years old 2.patients diagnosed as mrsa enterocolitis exclusion criteria: 1.infectious diarrhea caused by other pathogenic bacteria
sarah cannon outcomes registry

Conditions: Oncology

Summary: this is an investigational multi-site outcomes registry intended to collect information about a patient's cancer care. patients may enter the registry at any time during the patient's current stage in the continuum of care. the registries main objectives will be to measure and evaluate the effects of patient care throughout the care continuum, resulting in the identification of the most effective treatment options. objectives will encompass evaluations and analytics around safety, effectiveness, and improved efficiencies.

q

Eligibility criteria:
inclusion criteria: * 18 or older * patients that have been diagnosed with/ or are thought to have any form of cancer at any stage in the continuum of their care from screening through survivorship. * patient must have the ability to understand the nature of the trial and give written informed consent exclusion criteria: * there are no exclusion criteria for this outcomes registry
effect of perioperative oral pregabalin in total knee replacement

Conditions: Postoperative Pain

Summary: this interventional randomized control trial aim to determine efficacy and safety of oral pregabalin in improving after surgery pain control in patients undergoing total knee replacement surgeries under regional anesthesia. we'll compare the efficacy of pregabalin between two groups, pregabalin group and control group on the basis of their opioid consumption after knee operation.

after obtaining approval from the institutional ethical committee and informed written consent, 120 patients fulfilling the inclusion criteria will be included in this study. the patients will be randomly assigned into two equal groups; group p: pregabalin group and group c: control group. group p will receive oral capsule pregabalin 75mg one hour preoperatively and group c will not receive any premedication preoperatively. intraoperatively both groups will receive inj. midazolam 2 mg before subarachnoid block with hyperbaric bupivacaine 0.5% 2.5-3ml and fentanyl 15mcg in the operation theatre (ot). both groups will also receive parecoxib 40mg iv and paracetamol 1g intravenous (iv) as part of multimodal analgesia. both groups will receive dexamethasone 8mg iv prophylactically. postoperatively both groups will receive ultrasound guided adductor canal saphenous nerve block in the pacu with 0.2% bupivacaine 20-30ml \& dexmeditomidine1.0mcg/kg. group p will receive oral capsule pregabalin 75 mg q12hourly from the 1st dose for next 60 hours. group c will not receive any medication. both groups will receive paracetamol 1g iv q6hourly and rescue analgesia will be provided with oral oxycodone 5mg tds and morphine pca, in escalating manner as per patient requirement. for 24 hrs. after 24 hours both groups with receive tab paracetamol1 g q4hourly, ibuprofen 400 q8hourly along with tab oxycodone as prn q8hourly and pca morphine.

Eligibility criteria:
inclusion criteria: 1. age between 18 to 85 year 2. elective regional anesthesia. 3. able to follow study protocol exclusion criteria: 1. asa -iv 2. age \ 85 years 3. patients on pregabalin for chronic neuropathic pain. 4. patient under general anesthesia 5. patients with chronic liver failure 6. patients with chronic renal failure on hemodialysis 7. patients on opioid (\>3 month) 8. patient with complicated knee surgery

Keywords: total knee replacement postoperative pain pregabalin adductor canal block dexmedetomidine
ketamine versus morphine change pain profile

Conditions: Acute Pain

Summary: the aim of this study is to evaluate the efficacy of intravenous low dose ketamine infusion versus morphine infusion analgesia for pain reduction in abdominoplasty surgery

abdominoplasty is considered one of the most commonly performed cosmetic procedures. according to statistics from the international society of aesthetic plastic surgery, a total of 758,590 abdominoplasties were performed in the world in 2016. this is an increase of 72.95% in comparison with 2011, making it the fourth most common cosmetic procedure. given the increasing number of abdominoplasties performed, the importance of understanding the possible complications and morbidity associated with the procedure is critical. one of these complications is the postoperative pain. with adequate postoperative pain control, the patients met discharge criteria sooner and this helps in shortening the hospital stay, better overall patient satisfaction, and decreased hospital costs. therefore, the severity of this problem and the all drug agent used to prevent and treat postoperative pain best interest to be aware in the anesthesiologists. traditionally, analgesia for abdominal wall surgery is provided either by systemic drugs such as opioids, nonsteroidal anti-inflammatories, alpha 2 agonists and paracetamol or by epidural analgesia. however, opioids, such as morphine or fentanyl, remain the mainstay of postoperative analgesic regimens for patients after abdominal wall surgery. the pain is not always fully relieved by such agents, and often patients develop tolerance to them. the ever-increasing doses of opioids are clearly not without their adverse effects. (5) for this alternative approaches, which reduce the requirement for strong opioids post-operative, are required. recently, interest has focused on the use of n-methyl-d-aspartate (nmda) receptor antagonists for the management of postoperative pain. ketamine exerts its main analgesic effect by antagonism of nmda receptors that not only abolishes peripheral afferent noxious stimulation, but it may also prevent central sensitization of nociceptors as shown in animal studies with the excellent analgesic property even in subanesthetic doses. (6) various recently published studies have talked about the analgesic effect of low-dose ketamine (7,8) however, all of this study are relatively short procedure time, reduced surgical stimulation and small sample size. the aim of this study is to evaluate the efficacy of intravenous low dose ketamine infusion versus morphine infusion analgesia for pain reduction in abdominoplasty surgery

Eligibility criteria:
inclusion criteria: * asa physical status i or ii * patients aged between 18-50 years old. - exclusion criteria: * those who refused to participate * asa physical status iii, iv, patients younger than 18 years or older than 50 years old * super morbid obesity with bmi 50, history of epilepsy * patients having a history of parenteral or oral analgesics within the last 24 hours before * initiation of operation * those having an allergy to study agents.
study to compare hfsh-hp (fostipur) and hmg-hp(meriofert) in patients with polycystic ovary under a ivf/icsi cycle.

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary occurs in 15-20% of the population will be submitted to tra. whether it is associated with other signs or symptoms (polycystic ovarian syndrome) as if presented in isolation, its therapeutic management has special connotations sometimes favoring the low response although the standard is the tendency to hyperresponsiveness. although there are studies comparing the combination of fsh and lh and fsh in controlled hyperstimulation of these patients, there are no previous prospective randomized studies comparing administration of urinary fsh (hfsh-hp) with a combination of fsh and hcg (hmg hp). therefore the aim of this study is to prove that both drugs are comparable in the treatment of these patients. the test substances are marketed in spain (fostipur and meriofert, respectively) with an indication for use in these patients. in this study both medicines will be administered in a randomized way under the usual conditions in which it is used in routine clinical practice to compare the quantity of mature oocytes respect to the total oocytes obtained, as a primary outcome measure.


Eligibility criteria:
inclusion criteria: * female age between 18 and 38 years (inclusive) * women with a bmi under 30 kg / m2 * diagnosis of polycystic ovary syndrome (according to criteria of rotterdam) * women who want pregnancy * basal basal fsh levels under or equal 10 iu / l * infertility justify treatment with in vitro fertilization / intracytoplasmic sperm injection * to be included in a protocol with gnrh antagonist * presence of both ovaries and uterus able to support embryo implantation and pregnancy * absence of pregnancy before starting ovarian stimulation * written consent exclusion criteria: * severe male factor not allowing an in vitro fertilization / intracytoplasmic sperm injection with ejaculated sample * patients with low ovarian reserve * important endocrine-metabolic systemic diseases affecting pituitary, thyroid, adrenals, pancreas, liver or kidney * hiv seropositivity * to have frozen embryos from previous cycles of assisted reproduction * undiagnosed vaginal haemorrhage * poor response in previous cycles of in vitro fertilization with standard stimulation protocols * pregnancy, lactation or contraindication to get pregnant * malformations of the sexual organs incompatible with pregnancy * history of allergy to gonadotrophin preparations or its excipients * alcohol, drugs or psychotropic addiction * concurrent participation in another study * previous history of severe hyperstimulation syndrome * concomitant medication that may interfere with the study medication: different hormonal treatments used in the study, other thyroid hormones, antipsychotics, anxiolytics, hypnotics, sedatives, chronic treatment with inhibitors of prostaglandin

Keywords: reproductive techniques, assisted
effect of audible manipulation sound in non-specific cervicothoracic pain

Conditions: Pain; Disability

Summary: the aim of this study is to investigate the effect of auditory manipulation sound on perceived pain, satisfaction and disability in patients with nonspecific cervicothoracic pain.i̇ndividuals with nonspecific cervicothoracic pain will be included. the first group will be determined as those with an audible sound at the end of manipulation, and the second group will be determined as those without an audible sound at the end of manipulation. all evaluations and the patient's satisfaction level will be made before the application and 48 hours after the application.

before the application, the pain intensity of the individuals will be assessed with a visual analog scale, and the level of disability will be assessed with the 'neck pain and disability index'. neck mobility will be measured with a cervical inclinometer and spinal region fascia mobility modified schober test, and also the thoracolumbar fascia flexibility will be recorded. .

Eligibility criteria:
inclusion criteria: * clinical diagnosis of non-specific spinal pain * must be able to do exercise by alone exclusion criteria: * clinical diagnosis of neurological problems (alzheimer's, demans) * clinical diagnosis of deep vein thrombosis * clinical diagnosis of systemic and uncontrolled metabolic diseases( diabetes, thyroid,hypertension) * don't have pain while doing exercise

Keywords: neck pain manuel therapy
measurement repeatability in contemporary aberrometry

Conditions: Refractive Errors

Summary: wavefront scans are a common form of diagnostic test applied in preparing patients for laser eye surgery. an optical map of the eye is created by wavefront scanning, and information from these maps is used to program lasers used to correct focusing errors in the eye. here the investigators are comparing how repeatable measurements are with a new wavefront scanner and one that is already in widespread use.

aberrometers are used to measure each element of defocus (aberration) in an optical system. in lasik, information derived from aberrometry (scans performed using aberrometers) is used to program the pattern of laser pulses delivered by an excimer laser in therapeutic reshaping of the cornea to correct defocus. to do this accurately, aberrometry findings need to be repeatable and correspond closely to manifest refraction. here the investigators compare repeatability of measurements for a new aberrometer (peramis) versus the aberrometer most widely used in contemporary wavefront guided laser vision correction (idesign). the test aberrometer will be: peramis (schwind eye-tech solutions, kleinostheim, germany). control aberrometer will be: idesign (amo, santa clara, ca)

Eligibility criteria:
inclusion criteria: * myopic lasik candidates (manifest refraction spherical equivalent range 0 to -10 diopters with up to 6 diopters cylinder) or patients attending corneal service with stage ii-iii keratoconus or post-keratoplasty exclusion criteria: * visually significant co-pathology (cdva\<6/6) other than irregular astigmatism; * patients unable to complete a sequence of 2 good scans (acquisition diameter \>5mm) in one eye within 4 attempts
a study to determine the efficacy, safety and pharmacokinetics of gmi-1271 as adjunct to standard of care for the treatment of multiple myeloma

Conditions: Multiple Myeloma

Summary: this study will evaluate gmi-1271, a specific e-selectin antagonist, in multiple myeloma as adjunct to standard of care chemotherapy used to treat this disease.


Eligibility criteria:
inclusion criteria: 1. males and females ≥ 18 years of age 2. confirmed diagnosis of multiple myeloma 3. subjects with progressive mm who have received at least 1 prior therapy and who have already undergone or are not expected to undergo hematopoietic stem cell transplantation 4. subjects previously treated with an imid-based regimen or ineligible for an imid-based treatment regimen 5. subjects must be receiving treatment with a proteasome inhibitor-based regimen (bortezomib-based or carfilzomib-based) 6. adequate hepatic, renal, and cardiac function exclusion criteria: 1. intolerant to bortezomib or carfilzomib 2. progressing evidence of end organ damage attributed to the underlying disease 3. plasma cell leukemia 4. congestive heart failure 5. acute active infection 6. non-hematologic malignancy within the past 3 years except: a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, or c) prostate cancer with stable psa 7. significant peripheral neuropathy

Keywords: gmi-1271 bortezomib carfilzomib multiple myeloma
honey in idiopathic dilated cardiomyopathy

Conditions: Idiopathic Dilated Cardiomyopathy

Summary: background: honey, as a natural product produced by honey bees, has anti-oxidant, anti-microbial, anti-inflammatory and immunomodulator properties. a few reports suggest that honey might have positive effects on cardiovascular diseases. methods: this was a randomized controlled study, which was carried out on 50 children, aged 2 to 12 years, suffering from idiopathic dilated cardiomyopathy (idc). patients were randomly assigned into two equal groups: the honey group and the control group. in the honey group, honey was provided in a dose of 1.2g/kg/day for three months in addition to the traditional treatment of idc. the patients in the control group received only their standard treatment, without honey. the main outcome measure was the percent change in the ejection fraction (ef) and the fraction shortening (fs) shown in echocardiography.

background: honey, as a natural product produced by honey bees, has anti-oxidant, anti-microbial, anti-inflammatory and immunomodulator properties. a few reports suggest that honey might have positive effects on cardiovascular diseases. methods: this was a randomized controlled study, which was carried out on 50 children, aged 2 to 12 years, suffering from idiopathic dilated cardiomyopathy (idc). patients were randomly assigned into two equal groups: the honey group and the control group. in the honey group, honey was provided in a dose of 1.2g/kg/day for three months in addition to the traditional treatment of idc. the patients in the control group received only their standard treatment, without honey. the main outcome measure was the percent change in the ejection fraction (ef) and the fraction shortening (fs) shown in echocardiography. patients in each group were subjected to history taking, clinical examination and investigations, including ecg and echocardiography at baseline and end of the study. patients continued their standard treatment during the study. the honey used in the study was subjected to physicochemical analysis before use, and it was kept in closed containers away from light until the time of administration.

Eligibility criteria:
inclusion criteria: 1. echocardiographic diagnosis of dilated cardiomyopathy (dcm), based on the presence of left ventricular enlargement and systolic dysfunction with an ejection fraction \<45%. 2. the echocardiographic findings included left ventricular dilatation and systolic dysfunction, with or without mitral regurgitation exclusion criteria: 1. other types of cardiomyopathy 2. systemic or chronic illness, including cancer, endocrine disorders and sepsis 3. children with diabetes mellitus 4. ischemic heart disease diagnosed by coronary angiography or a history of myocardial infarction 5. systemic hypertension with a blood pressure \>170/100 mm hg -